Small cell lung cancer Cancer Malignant neoplasm of bronchus and lung
Conditions
Interventions
This is a single centre non-randomised observational imaging feasibility study. There will be a maximum of 4 MRI scans (interventions) over a 1 year period and the total duration recruitment will be 2
Sponsors
Cambridge University Hospitals NHS Foundation Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Ability to give written informed consent 2. Aged greater than 18 years, either sex 3. Histologically or cytologically confirmed small cell lung cancer 4. No previous malignancy 5. No prior chemotherapy 6. Satisfactory renal function (ethylenediaminetetraacetic acid [EDTA] clearance greater than 60 ml/min) 7. Satisfactory World Health Organization (WHO) performance status 0, 1 or 2
Exclusion criteria
Exclusion criteria: 1. Prior chemotherapy or radiotherapy to primary tumour 2. Central nervous system (CNS) disease 3. Previous or coexistent malignancies 4. Pregnancy or breastfeeding 5. Any other medical condition making participation in a clinical trial undesirable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of the subset of SCLC patients at high risk for developing brain metastases, based on novel imaging at diagnosis, correlated retrospectively with clinical outcome. | — |
Secondary
| Measure | Time frame |
|---|---|
| Radiological disease progression: 1. Local incidence of asymptomatic brain metastases detected by conventional MRI at diagnosis 2. Local incidence of brain metastases detected after chemotherapy by conventional MRI | — |
Countries
England, United Kingdom
Outcome results
None listed